Status:
COMPLETED
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Lead Sponsor:
Beth Israel Medical Center
Conditions:
Colorectal Cancer
Nausea
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve p...
Detailed Description
OBJECTIVES: * To assess the prevalence of delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-emetic medications during the first course of an oxaliplatin-based che...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of colorectal cancer
- Currently receiving OR scheduled to receive the first course of either of the following chemotherapy regimens:
- mFOLFOX6
- FOLFOX7
- No clinical or imaging evidence of brain metastasis
- PATIENT CHARACTERISTICS:
- Able to maintain a diary and complete a standardized quality of life questionnaire in English
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 90 days since prior aprepitant
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00729677
Start Date
June 1 2005
End Date
December 1 2008
Last Update
October 26 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Medical Center - Philipps Ambulatory Care Center
New York, New York, United States, 10003